TOP1 and SYMPK

Number of citations of the paper that reports this interaction (PubMedID 12549820)
3

Data Source:
BioGRID (unspecified method)

		TOP1	SYMPK
Description		DNA topoisomerase I	symplekin
Image
GO Annotations	Cellular Component	Nuclear Chromosome P-body Fibrillar Center Nucleus Nucleoplasm Nucleolus Replication Fork Protection Complex Protein-DNA Complex Perikaryon	Nucleoplasm Cytoplasm Cytosol Cytoskeleton Plasma Membrane Bicellular Tight Junction Nuclear Stress Granule
	Molecular Function	RNA Polymerase II Proximal Promoter Sequence-specific DNA Binding DNA Binding Chromatin Binding Double-stranded DNA Binding Single-stranded DNA Binding RNA Binding DNA Topoisomerase Type I Activity Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Protein Domain Specific Binding Supercoiled DNA Binding	Protein Binding
	Biological Process	DNA Replication DNA Topological Change Chromatin Remodeling Chromosome Segregation Circadian Rhythm Programmed Cell Death Viral Process Phosphorylation Peptidyl-serine Phosphorylation Circadian Regulation Of Gene Expression Embryonic Cleavage Response To Drug	MRNA Splicing, Via Spliceosome Termination Of RNA Polymerase II Transcription MRNA Polyadenylation MRNA Export From Nucleus Cell Adhesion MRNA 3'-end Processing Negative Regulation Of Protein Binding Positive Regulation Of Protein Dephosphorylation
Pathways		SUMOylation of DNA replication proteins	Transport of Mature mRNA Derived from an Intronless Transcript mRNA Splicing - Major Pathway mRNA 3'-end processing RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs
Drugs		Irinotecan Topotecan Camptothecin Edotecarin Lucanthone Elsamitrucin 7-ethyl-10-hydroxycamptothecin Sodium stibogluconate Cositecan XMT-1001 2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM 4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE
Diseases
GWAS		Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction) ( 28560309) Antipsychotic drug-induced weight gain in schizophrenia ( 31447353) Cholesterol, total ( 24097068 20686565) LDL cholesterol ( 24097068 20686565) LDL cholesterol levels ( 28334899) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Male-pattern baldness ( 28196072) Metabolite levels ( 23823483) Total cholesterol levels ( 28334899) Urate levels ( 31578528)	Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy) ( 30940143) Colon cancer ( 28295283) Colorectal cancer ( 28295283) Coronary artery disease ( 29212778) Eosinophil counts ( 27863252)
Interacting Genes		59 interacting genes: APAF1 APP ATM BARD1 BRCA1 BTBD1 BTBD2 BUB3 CASP3 CASP6 CDK8 CKAP5 CSNK2A1 CSNK2A2 DDB2 ELK3 ERCC8 ERG FSHR GEMIN4 IL7R IRF4 IRF8 IRF9 JAK1 JUN KMT2A LIG4 LSM4 MDM2 NCL NCOA6 PDE10A PPP2R2B PRB1 PRKDC PYGM RBL1 RBL2 RCVRN SF3B1 SFPQ SNRNP70 SNW1 SRPK2 SRSF1 SRSF11 SUMO1 SYMPK TARBP2 TDP1 TOPORS TP53 TRIM32 TUBD1 U2AF2 UBE2I XRCC5 XRCC6	7 interacting genes: CSTF2 HSF1 HTT RIN3 TOP1 UBE2I YBX3
Entrez ID		7150	8189
HPRD ID		00535	09090
Ensembl ID		ENSG00000198900	ENSG00000125755
Uniprot IDs		P11387 Q9BVT2	A0A024R0R6 Q92797
PDB IDs		1A31 1A35 1A36 1EJ9 1K4S 1K4T 1LPQ 1NH3 1R49 1RR8 1RRJ 1SC7 1SEU 1T8I 1TL8	3O2Q 3O2S 3O2T 3ODR 3ODS 4H3H 4H3K
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?